title: The immninent dawn of SPRMs in obstetrics and gynecology.
abstract: Selective progesterone receptor modulators (SPRMs) have been developed since the late 70s when mifepristone was first described. They act through nuclear progesterone receptors and can have agonist or mixed agonist antagonist actions depending on the cell and tissue. Mifepristone has unique major antagonist properties allowing its use for pregnancy termination. Ulipristal acetate has been marketed in 2009 for emergency contraception and has been recently approved for preoperative myoma treatment. Further perspectives for SPRMs use include long term estrogen free contraception, endometriosis treatment. However long term applications will be possible only after confirmation of endometrial safety.
authors.affiliation: Obstetrics, Gynecology and Reproductive Medicine Department, AP-HP, Hospital Tenon, UPMC Paris 06, Paris, France. nathalie.chabbert-buffet@tnn.aphp.fr
authors.forename: Nathalie
authors.initials: N
authors.lastname: Chabbert-Buffet
authors.forename: Axelle
authors.initials: A
authors.lastname: Pintiaux
authors.forename: Philippe
authors.initials: P
authors.lastname: Bouchard
mesh_terms: D003267:Contraception; D005260:Female; D006176:Gynecology; D006727:Hormone Antagonists / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D015735:Mifepristone / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D009774:Obstetrics; D011980:Receptors, Progesterone / Q000819:agonists / Q000037:antagonists & inhibitors
chemical_list: D006727:Hormone Antagonists; D011980:Receptors, Progesterone; D015735:Mifepristone